50786
document
A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia . Patient preference for benign prostatic hyperplasia ( BPH ) treatment with the α ( 1 ) -blockers , tamsulosin or silodosin , was compared using patient-reported outcomes . Japanese patients with lower urinary tract symptoms associated with BPH were randomly allocated to either the T-S group ( tamsulosin 0.2 mg orally once daily for 4 weeks then silodosin 4 mg orally twice daily for 4 weeks ) or the S-T group ( silodosin 4 mg orally twice daily for 4 weeks then tamsulosin 0.2 mg orally once daily for 4 weeks ) . The primary endpoint was the preferred drug for treatment continuation at 8 weeks , determined by a patient-reported questionnaire . In total , 102 patients ( mean age 70.3 years ) were enrolled and 84 ( n = 42 per group ) completed the study . A significant difference was observed between the proportion of patients who preferred tamsulosin ( 59/84 patients ; 70.2 % ) and those who preferred silodosin ( 18/84 patients ; 21.4 % ) . A major reason for preference of either drug was 'good efficacy ' . Incidence of adverse effects was significantly lower with tamsulosin ( 3/91 patients ; 3.3 % ) than with silodosin ( 25/88 patients ; 28.4 % ) . These findings indicate that tamsulosin is very effective for BPH , has few adverse effects and that patients want to continue to use it .
50787
Intervention_Pharmacological
tamsulosin
50788
Intervention_Pharmacological
silodosin
50789
Participant_Condition
lower urinary tract symptoms
50790
Participant_Condition
benign prostatic hyperplasia
50791
Participant_Condition
lower urinary tract symptoms
50792
Participant_Condition
BPH
50793
Participant_Sample-size
102
50794
Participant_Age
mean age 70.3 years